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Abstract
Background: Human papillomavirus (HPV) is a necessary cause of cervical dysplasia and cancer, and of genital
warts. Few studies have examined attitudes to HPV vaccination since the introduction of HPV vaccines. We aimed
to investigate the reasons for young women’s acceptance or rejection of the quadrivalent HPV vaccine after its
general availability in Denmark.
Method: A literature review assessed attitudes towards HPV vaccination and the information was used to identify
relevant questions for telephone and focus group interviews with women aged 16-26 who had decided to receive
or reject HPV vaccination. 435 women across Denmark were interviewed by telephone. Qualitative interviews were
undertaken in focus groups with 33 women living in Odense who had completed the telephone survey. Four
focus groups were set up according to age (16-20 and 21-26 years of age) and acceptance/rejection of the
vaccine.
Results: Of 839 women initially contacted by telephone, 794 were included, 411 (49%) said they accepted
vaccination but only 201 (24%) had actually received the vaccine and these latter were interviewed. 242 women
said they refused vaccination of which 234 were interviewed. Women who were undecided were excluded from
the study. Prevention of cervical cancer was the main driver for acceptance of the vaccine, followed by parental
encouragement and financial support, personal experience of someone with cancer and recommendation by
health-care professionals. The greatest barrier to vaccination was its cost. A lack of information about the benefits
of vaccination for sexually active women was also an important barrier and the older participants in particular
considered that they were too old to be vaccinated. Knowledge about HPV and its role in the development of
cervical cancer and genital warts was poor.
Conclusions: The difference between intention to be vaccinated and starting vaccination was considerable, and a
large proportion of women aged 16-26 did not wish to be vaccinated. If the most important barriers to
vaccination were addressed (cost and a lack of information about vaccination benefits), it is likely that the uptake
of vaccination in Denmark would increase substantially.
Background
Persistent infection with certain sexually transmitted
types of human papillomavirus (HPV) is a necessary
cause of cervical dysplasia and cancer, and of genital
warts [1]. In Europe, it is estimated that 37,500 women
are affected by cervical cancer every year [2]. Genital
warts are one of the most prevalent sexually transmitted
diseases in Europe; the cumulative incidence in women
in four Nordic countries has been estimated at more
than 10% [3].
Two vaccines against HPV have recently become
available - the bivalent vaccine Cervarix® (GSK) and the
quadrivalent vaccine Gardasil® (Merck) - both of which
protect against HPV types 16 and 18, which cause about
70% of cervical cancers. The quadrivalent vaccine also
protects against infection with HPV types 6 and 11,
which cause about 90% of cases of genital warts [4-9].
HPV vaccine coverage is thus an important public
health concern and understanding the reasons for
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increasing compliance.
Attitudes before introduction of the vaccine
A number of studies have examined the potential recep-
tion of a HPV vaccine among parents and young people
before approval and widespread introduction. A systematic
review of international literature published before January
2007, that was carried out in connection with a Danish
Health Technology Assessment (HTA) of HPV vaccina-
tion [10], showed that attitudes towards HPV vaccination
were mostly positive and that 70-90% of parents said they
wanted to have their children vaccinated [10-18]. The
intention to vaccinate depended on a number of factors,
including the knowledge that HPV is the cause of cervical
cancer, confidence in the vaccine’s safety and efficacy
[11,12,14,16-22], and the perception of HPV infection or
cervical lesions as common occurrences with a potentially
serious outcome [12,15,17,21-24]. Parents were also influ-
enced by the cost of the vaccine [12,18,21,24,25] and
whether it had been recommended by a general practi-
tioner (GP) or ‘significant others’ (e.g. family member)
[12,13,17,18,21,22]. Some USA-based studies found that
parents’ fear that HPV vaccination might be seen as an
endorsement of promiscuity was a barrier to acceptance
[11,13,16,19,21,22]. Parental acceptance of vaccination also
depended on the age [11,16,19,20,22] and sex [15,20,22] of
their children, as well as their own experiences of sexually
transmitted infections (STI) or cancer [21,24].
The empirical studies of the Danish HTA of HPV vac-
cination showed that the majority of parents and young
men and women interviewed had positive attitudes
towards HPV vaccination [10], although the participants
expressed a need for more information about the vac-
cine and its safety. Most felt that HPV vaccination
should be integrated into the free childhood-immunisa-
tion programme to secure equal access and to ensure
that vaccination was achieved before sexual debut. How-
ever, parents of teenagers also wanted their children
vaccinated, despite the possibility that they had already
been exposed to HPV. Participants aged 18-22 years
expressed a desire to be vaccinated, but doubted they
would actually do so if they had to pay for it themselves.
The knowledge that HPV is sexually transmitted did not
have a negative effect on Danish participants’ attitudes
towards the vaccine; vaccination was not seen as stigma-
tising or promoting sexual promiscuity and men and
women were considered to be equally responsible for
the prevention of sexually transmitted infections (STIs).
Attitudes after introduction of the vaccine
The participants in the previously mentioned studies
were asked about their attit u d e st ot h eH P Vv a c c i n e
before it became readily available or available free-of-
charge. As an expression of intentions regarding a
hypothetical situation, such results may be an imprecise
indicator of behaviour in a real situation [26]. The lit-
erature review we carried out in preparation for the pre-
sent study showed that few studies have been carried
out on attitudes to and acceptance of HPV vaccination
after the vaccine has been approved and has become
readily available in many countries.
Since the approval of the first HPV vaccine in 2006 in
the USA [27], many countries have introduced HPV vacci-
nation into national health-care systems, although the
choice of the vaccine recommended, organisation and
financing, and the age and sex of the recipients vary con-
siderably. Most countries have selected the quadrivalent
vaccine and while most recommend HPV vaccination for
girls only, Austria and Greenland also offer the vaccine to
boys [9].
In Denmark, the quadrivalent vaccine was approved and
became available in September 2006. Since January 2009 it
has been offered free-of-charge within the childhood-
immunisation programme for girls aged 12 years. A catch-
up programme for girls aged 13-15 years (girls born in
1993-95) started in October 2008. The Danish National
Board of Health informs all girls in this target group
directly by mail and has produced information material
about HPV vaccination and cervical cancer which is avail-
able in doctors’ offices and on the Internet. The Danish
Cancer Society is conducting an information campaign
that has included the training of 200 ‘ambassadors’,i . e .
young women who give lectures on HPV vaccination at
educational institutions across the country. The vaccine
manufacturer has also run a media-based information
campaign focused on ‘vaccination against cervical cancer’.
The uptake of free HPV vaccination in Denmark has
been massive, and by January 31st 2009, 71% of girls
born in 1993, 76% of girls born in 1994, and 67% of
girls born in 1995 had been vaccinated [28]. While the
vaccine is also approved for women aged 16-26 years,
these women, like all boys and men, must pay about
470 euros if they want to be vaccinated.
The aim of the present study, the first of its kind in a
Danish context, was to examine the attitudes to HPV
vaccination of young women aged 16-26 years after the
quadrivalent HPV vaccine became readily available and
after its introduction into the free childhood-immunisa-
tion programme. Now that childhood HPV vaccination
is actually available, are young Danish women above the
age of 15 taking the initiative to be vaccinated and what
are the factors determining acceptance or refusal of
vaccination?
Methods
For this study, we used methodological triangulation to
increase the reliability and validity of the results [29]. A
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multiple-choice questionnaire and qualitative focus
group interviews centred on issues identified in the pre-
viously described literature review. The quantitative part
of the study was used to investigate patterns and fre-
quency of attitudes towards vaccination. The qualitative
and central approach involving focus group interviews
was used to examine in depth perceptions of the dis-
eases covered by HPV vaccination, treatments and pre-
ventive methods, enabling us to explain patterns of
meaning related to attitudes towards HPV vaccination.
We thus acquired knowledge about the qualities of the
phenomenon regardless of its frequency [30]. The quali-
tative research methods also allowed us to explore the
reasons for differences between intention and action in
this particular socio-cultural context [31], and were par-
ticularly suitable for examining health-related choices
concerning the prevention of HPV infection. The study
did not require approval from the Danish National
Committee on Biomedical Research Ethics. The metho-
dology and analyses were discussed in an ad-hoc com-
mittee formed by the author, the assistant
anthropologist, an independent, experienced anthropolo-
gist and a statistician.
Literature review
To supplement the literature review carried out by the
author in connection with the Danish HTA [10], we
performed an updated literature search on PubMed
using the English search terms (MeSH and free text; sin-
gular and plural terms): <HPV>, <human papilloma
virus>, <wart-virus>, <vaccines>, <vaccination>, <immu-
nization>, <vaccine programme> combined with <par-
ents>, <youth>, <young>, <youngster>, <people>,
<adolescent>, <teenage>, <attitude>, <acceptance>,
<accept>, <knowledge>, <barriers>, <cultural> to iden-
tify papers published between January 2007 and January
2009. Danish search terms: <Vaccination> (vaccination),
<patient> (patient) combined with <holdninger> (atti-
tudes), <accept> (acceptance) and <viden> (knowledge)
were also used. The papers found were used to identify
relevant questions for the participants in the telephone
interviews and focus groups.
Telephone interviews
Telephone interviews were chosen as a method of pre-
senting a statistically significant number of women with
a limited range of open-ended questions regarding atti-
tudes towards HPV vaccination. A structured-question
interview guide and computer-assisted telephone inter-
viewing (CATI) software (Sawtooth) was used by profes-
sional interviewers (DMA/Research, Aarhus, Denmark).
The guide included questions on the level of education
of the women and their parents, the sources of their
knowledge about HPV, if and with whom they had dis-
cussed HPV vaccination, and the main reasons for their
choice. Based on the literature review, a number of pre-
defined response options to each question were inserted
in the CATI guide for the interviewers to mark if the
participant’s response corresponded to it, for instance
“because my parents paid for it” or “because I’ve already
been sexually active”. Multiple responses were allowed.
For each question, the CATI guide also included an
open option (’other’) that allowed the interviewers to fill
in answers not corresponding to the predefined
response options using free text. These free text answers
were subsequently coded into main topics. In some
cases, these answers could be included in the predefined
response options after all; in other cases new response
categories were created.
For the telephone interviews, participants were
recruited via randomised calls to a geographically repre-
sentative sample of households in Denmark in mid Jan-
uary 2009. To avoid a regional or city/country bias, this
method implied calling publicly available telephone
numbers to households across the country without prior
knowledge about their residents. Women aged between
16-26 years who had heard of HPV vaccination were
informed about the purpose of the study and invited to
participate anonymously. To be included in the ‘accept-
ing HPV vaccination’ group, they had to have already
started or finished vaccination. Those who had decided
not be vaccinated were included in the ‘refusing HPV
vaccination’ group. Those who were undecided were
excluded from the study (figure 1). Telephone interviews
were ended when a representative number of women,
corresponding to each region’s quota of the total popu-
lation, had participated.
Focus group interviews
Focus group interviews were chosen with the aim of
creating a confidential setting where women in a com-
parable situation could openly discuss their reflections
and choices. The volunteers were divided into four
groups by acceptance or rejection of HPV vaccination
and by age to encourage more open and honest discus-
sion [32]. The aim was to gain an insight into as broad
a range of perspectives on HPV vaccination as possible.
As a social research method, the combination of group
interaction and the focus on a particular topic in focus
groups are suitable for producing empirical data on the
social construction of meaning. This includes those
social repertoires of meaning that are usually taken for
granted and that people draw on, interpret and act on
in their everyday practices along with significant others
[32,33]. One of the purposes of a focus group is to help
t h ep a r t i c i p a n t se x p r e s sr e l e v a n tp a r t so ft h i ss i l e n t
knowledge [34]. Focus groups can thus generate an
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the level of consensus and conflicts in a given area
[35,36].
Focus group interviews were carried out with women
who had completed the telephone interview and who were
living in Odense. Participants were invited immediately
following the telephone interview on a first come, first
served basis until a sufficient number of participants for
each group was attained. Volunteers were divided into
four groups: two groups of women who accepted HPV
vaccination and had begun or completed the vaccination
series (eight women aged 16-20 years and seven women
aged 21-26 years) and two groups who did not want to be
vaccinated (ten women aged 16-20 years and eight women
aged 21-26 years). No additional personal information was
collected about these women, who gave their informed
consent and also participated anonymously in the focus
groups. Participants also only heard the first names of
each other. A total of 33 women, all ethnic Danes and
mostly students, participated in the focus group discus-
sions (Figure 1).
The focus groups were moderated by the author and a
colleague, using a semi-and funnel structured interview
guide that involved going from general questions about
attitudes to vaccines in general to more specific ques-
tions about HPV vaccination. Open-ended questions
were used to capture information not anticipated by the
literature review [32]. The discussions were transcribed
verbatim and analysed using specific software for hand-
ling qualitative data, Nvivo (QSR International). A dis-
course theoretical approach to the relations between
language and the social construction of meaning was
used to analyse the data [37]. This comprised an analysis
of the terminology used to speak about the subject and
the ways this related to other issues. First, the data were
coded by topic raised during the discussions and then
the most important themes within each topic were iden-
tified. The frequency and connections between topics
and themes was then analysed to obtain a pattern of the
relative importance of the different topics and themes
for the participants and thus the significant drivers for
and barriers against HPV vaccination. All
Women initially
contacteda
N = 839
Women considered
for inclusion
N = 794 (94.6%)
Excluded: never
heard about HPV vaccination
N = 45 (5.4%)
Excluded: not sure about
HPV vaccination
N =141 (16.8%)
Women refusing
HPV vaccination
N = 242 (28.8%)
Women accepting
HPV vaccination
N = 411 (49.0%)
Excluded: not yet started
HPV vaccination
N = 210 (25.0%)
Included: women accepting
HPV vaccination
N = 201 (24.0%)
Aged 16 20 years = 100
Aged 21 26 years = 101
Included: women refusing
HPV vaccination
N = 234 (27.9%)
Aged 16 20 years = 102
Aged 21 26 years = 132
Women included in telephone survey
Included: women accepting
HPV vaccination
N = 15
Aged 16 20 years = 8
Aged 21 26 years = 7
Included: women refusing
HPV vaccination
N = 18 
Aged 16 20 years = 10
Aged 21 26 years = 8
Women included in focus groups
(from Odense)
a Percentages were calculated 
with the denominator 839
Excluded: interview not completed
N = 8 (1.0%)
Figure 1 Description of groups of participants in the telephone survey and focus groups.
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alternative interpretations sought with the assisting
anthropologist, an additional anthropologist not involved
in the project and a statistician. Disagreements concern-
ing the focus groups were solved using Spradley’s analy-
tical process of resolution of qualitative data [38]. The
quotes given in the results section illustrate the partici-
pants’ most pertinent reflections.
Results
Results of the updated literature review
The results from the updated literature review mostly
showed support for the results of earlier studies [39-49].
Among the studies conducted before widespread avail-
ability of the vaccine, some suggested that the percep-
tion of whether the vaccine is aimed at preventing HPV
infection, cervical cancer or genital warts can be decisive
to acceptance [48,49]. Jones & Cook showed that among
male university students in the USA, interest in HPV
vaccination rose considerably when the vaccine was pre-
sented as a means of preventing genital warts [46]. They
also suggested that personal experiences (e.g. number of
sexual partners, history of STIs or HPV infection) more
often acted as drivers rather than barriers to acceptance
of HPV vaccination [46].
Only a few of the identified studies had been con-
ducted after the introduction of HPV vaccination
[50-53]. Stretch et al. described how the attitudes of par-
ents in the UK had been confirmed rather than altered
by receiving more information about HPV and cervical
cancer [53]. Ogilvie et al. reported that 70% of Canadian
parents said they would like their daughters to benefit
from free vaccination against HPV, although it was not
reported how many girls had actually started the vacci-
nation series [51]. In a USA-based study by Rosenthal et
al., 26% of health-care providers had started or com-
pleted the vaccination of adolescent girls in their care
[50]. Also, n the USA, Kahn et al. reported that while
66% of the young women in their study intended to be
vaccinated against HPV, only 5% had actually started
[52]. These few studies indicate that, although intention
to vaccinate remains strong when the HPV vaccine
becomes available in a country, there can be consider-
able discrepancy between intention and action.
Survey sample
Of the 839 women initially contacted by telephone, 794
(94.6%) had heard of HPV vaccination and was thus
considered for inclusion (Figure 1). 141 women (corre-
sponding to 16.8% of all women contacted) were
excluded from participation in the study, however,
because they were undecided as to whether they wanted
HPV vaccination. 242 women (corresponding to 28.8%
of all women contacted) stated that they did not want
to be HPV vaccinated. Among these women, 234 tele-
phone interviews were completed. 411 women (49% or
nearly half of all women contacted) stated that they
wanted HPV vaccination, but only approximately half of
these women, i.e. 201 women (24%) had actually started
or completed the vaccination series and were included
for telephone interviewing. 210 of the women stating to
want HPV vaccination (25% of all women contacted)
were thus excluded. A total of 435 women in the rele-
vant age group were interviewed by telephone. The
majority of women in the survey had low income, most
being students (81.5%); although tuition in Denmark is
free, the average grant for students living alone is €683.
The others were working (14.2%), apprentices (2.1%)
and unemployed (2.2%).
Focus groups: Perceptions and knowledge about HPV
vaccination and HPV-related diseases
Overall, the focus group participants’ views on vaccines
already integrated into the Danish childhood-immunisa-
tion programme and travel vaccines were positive. The
participants said that vaccination was a good health-care
intervention which is routinely accepted. Nor were the
women who refused HPV vaccination against HPV vac-
cination as such.
The focus group participants’ knowledge about HPV
as an infectious agent, and the prevalence of cervical
dysplasia and cervical cancer was poor, for both those
who accepted and those who refused HPV vaccination.
With a few exceptions, the women were not aware that
the vaccine only protects against cervical cancers that
are caused by HPV 16 and 18 (representing about 70%
of all cancers); most thought that all cervical cancers
could be prevented if vaccination occurred before sexual
debut. This misconception was partly founded on per-
ceptions of the nature of vaccines in general, and was
related to the idea that the vaccine would not have been
included in the Danish childhood-immunisation pro-
gramme if this was not the case. The focus groups parti-
cipants were uncertain of the benefits of vaccination for
themselves because most of them were already sexually
active. Their knowledge about genital warts was also
poor, particularly among those who refused HPV vacci-
nation; only a few women in the focus group of 21-26-
year-olds who accepted HPV vaccination knew that the
vaccine can also prevent genital warts.
None of the focus group participants had received
information about HPV vaccination from their GP, and
only one had received information from her gynaecolo-
gist. Most of them had heard about vaccination against
cervical cancer from the media-information campaign.
However, many focus group participants stated that they
did not feel concerned because the campaign seemed to
target girls aged 12-15 years, and the women refusing
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outside the target group for vaccination.
There simply hasn’t been enough information clearly
saying: “hey, this one’s intended for you too!” -o rf o r
my age group. I had no idea what the criteria were.
That’s not given anywhere. I haven’th e a r da b o u t
that at all. In this situation, I just think that as I
hadn’t found out about it either in school or in the
news, how important can it be, when there is so little
information? [18-year-old focus group participant
refusing HPV vaccination]
Many of the focus group participants refusing vaccina-
tion felt that the National Board of Health should con-
tact young women over 15 years old (as they do for
HPV vaccination of 12-15 year old girls and other
h e a l t h - c a r ei s s u e s ) ,a n di n f o r mt h e md i r e c t l ya b o u tt h e
efficacy of the vaccine in sexually active women [5].
Once - I don’t remember if it was when I turned 18 -
I received a letter [from the National Board of
Health] inviting me to go for a check-up for chlamy-
dia. I don’t understand why they don’t do that with
this as well. They could send a letter to those who
don’t get the vaccine for free, inform them about
HPV and cervical cancer and other diseases and
about the availability of a vaccine, and advise them
to go to see their GP for more information, or some-
thing like that, so that we’d learn a bit more about
it. Because it seems that a lot of us haven’th e a r do f
this before and that’s quite worrying when you think
about how serious it is. They should do more to
reach out to those who are exposed. [20-year-old
focus group participant refusing HPV vaccination]
The focus groups showed that the sexual transmission
of HPV was associated with a perception of a high risk
of infection because sex was regarded as a natural part
of life and not something one could (or would want to)
avoid. This was in contrast to smoking or sun-bed use,
for example, that were often cited as behaviours asso-
ciated with an increased risk of cancer. Thus, for the
focus group participants, the fact that HPV vaccination
protects against a sexually transmitted disease was not a
barrier to the acceptance of vaccination.
Results across the quantitative and qualitative studies:
Drivers for HPV vaccination
Prevention of cervical cancer
The results from the survey showed that prevention of
cervical cancer was the main reason for accepting HPV
vaccination, with parental advice and experience of can-
cer with close relatives as the second and third most fre-
quent reasons (Table 1). In the focus groups with
women accepting HPV vaccination, the women elabo-
rated on this by saying that any measure to prevent can-
cer was welcome. For some, the acceptance of
vaccination was higher because they knew somebody
who had had cancer. Several focus group participants
said that they thought cancer and related diseases were
frequent and that they were as likely as anyone to
become ill.
In the focus groups, personal experiences with HPV-
related diseases could be a driver for accepting HPV
vaccination. While the younger women knew little about
cervical dysplasia and cervical cancer, the older women
were better informed. They knew, for example, that cer-
vical dysplasia does not necessarily progress to cancer,
but that it can be highly distressing (see also [54]). Sev-
eral of the older focus group participants knew that they
had already been exposed to HPV: one woman had been
diagnosed with HPV, two had had cervical dysplasia and
one had an ex-partner who had genital warts.
Only few of all participants stated prevention of geni-
tal warts as a reason to be vaccinated against HPV (for
the survey results see Table 1). The focus group partici-
pants explained that genital warts is a taboo disease that
is given less public attention than other sexually trans-
mitted diseases such as Chlamydia and AIDS (see also
[55,56]), but when informed, they generally welcomed
the fact that HPV vaccination can also prevent genital
warts as an additional benefit.
The importance of significant others in decision-making
The survey showed that women who accepted HPV vac-
cination had discussed the vaccine with other people
much more frequently than those who refused HPV vac-
cination: 92% compared with 70%. More women who
accepted HPV vaccination had talked with their parents
(the survey did not distinguish between fathers and
mothers) and friends than those who refused HPV vac-
cination (Table 2). Also, more of the women accepting
HPV vaccination had talked about the vaccine with their
GP than those who refused it. The other people that the
women talked with were typically other family members
(Table 2).
In the survey, many more women accepting HPV vac-
cination than women rejecting vaccination said to have
heard about the vaccine from their parents. Another
major difference between the groups was that the
women rejecting HPV vaccination had mainly - and
much more frequently than women accepting vaccina-
tion - heard of the vaccine on TV (Table 3).
The survey showed that parents of women accepting
HPV vaccination tended to have a higher level of educa-
tion than parents of women refusing:
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11%, for mothers and fathers respectively;
￿ had a university degree: 24% and 38% vs. 14% and
18%, for mothers and fathers respectively.
The focus group participants specified they had talked
about the vaccine mainly to their mothers and female
friends, but it was their mothers who were most influen-
tial, particularly for the younger participants, when they
took the initiative to seek information and make an
appointment with a doctor for their daughters. In con-
trast, almost half of the older focus group participants
had spoken to their GP about HPV vaccination at their
own initiative, and many expressed surprise that their
GP had not talked to them about the vaccine and
seemed to have poor knowledge of the subject when
asked.
HPV vaccination seen as a fresh start
The focus group of women aged 21-26 years accepting
HPV vaccination said that many of their peers were not
being vaccinated because they thought it was already
too late. Many of these participants, however, consid-
ered that with HPV vaccination and a negative cervical-
smear result, they could make a fresh start:
Y o uk i n do fh a v et os a y :w e l l ,t h i si sw h e r ew es t a r t
afresh. With all those people I meet from now on, I’m
protected, right? I can’tc h a n g ew h a tI ’ve already
done. [24-year-old focus group participant accepting
HPV vaccination]
The younger focus group participants, in particular,
said that they would actually like to know more about
the benefits of the vaccine in sexually active women.
They mostly understood that the more sexual partners a
woman had had, the higher the risk that she had already
been exposed to HPV and therefore the lower the
expected benefit from vaccination. Although most of the
16-20-year-old focus group participants who had been
HPV vaccinated were already sexually active, they hoped
that they might still benefit from the vaccine.
I had already been with someone when I got the vac-
cine, so I was a bit like, shall I get it when there’sa
risk that it won’t even do any good? But then I
thought that I might as well get it while there’s still a
Table 1 Main reasons for accepting HPV vaccination
Women accepting HPV vaccination (%)
1. Reason Age 16-20 years (N = 100) Age 21-26 years (N = 101)
To prevent cervical cancer 84 83
Recommended by parents 33 13
Close relatives with cancer 18 14
Because it is available 21 10
Other
a 51 9
Recommended by GP 6 11
High risk of cervical cancer 3 8
High risk of HPV infection 5 4
To prevent genital warts 5 4
Recommended by friends 2 4
Recommended by sibling 0 2
Recommended by partner 1 0
aOther included: various (e.g. work-related) experiences with cancer, vaccine paid for by parents or participating in a vaccine trial.
Table 2 Who did you talk to about HPV vaccination?
Women accepting HPV vaccination (%) Women rejecting HPV vaccination (%)
Age 16-20 years (N = 100) Age 21-26 years (N = 101) Age 16-20 years (N = 102) Age 21-26 years (N = 132)
Parents 72 68 42 27
Friends 64 60 50 47
General practitioner 16 34 5 8
Siblings 12 21 14 9
Partner 1 10 2 4
Others 3 4 4 5
Colleagues 0 4 1 5
School/college doctor 0 1 0 0
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group participant accepting HPV vaccination]
A lot of my friends are also getting the vaccine
because the attitude is like, if we wait for another 2
or 3 years, well, then we will probably get it [an HPV
infection]. The chances that we’re not with one, two,
three partners within a couple of years, well, it’s
small, after all. So, we’re right in that age group
where, either, you get it now, or the chances that you
get infected are simply too high. [20-year-old focus
group participant accepting HPV vaccination]
Cost versus vaccine benefits for sexually active women
Most of the focus group participants accepting HPV
vaccination said they had been vaccinated simply
b e c a u s et h ev a c c i n ew a sa v a i l a b l ea n dt h e yh a dn oc o n -
cerns about possible side-effects. Only the cost of the
vaccine had made them hesitate. For almost all the
younger and most of those older focus group partici-
pants, the vaccine had been partially or entirely paid for
by their parents; many of the younger women said they
would probably not have been vaccinated if they had
had to pay themselves. The women in the focus groups
explained that they had weighed up the benefits of vac-
cination after the onset of sexual activity against the
cost and the balance tipped in favour of vaccination
when parents helped out financially.
I also think it’s got to do with the money, whether
you’ll spend it if there’s a great risk that you’ve
already been infected [with HPV]. My parents paid
for it, so to me, it was like...well, I’d just like to get it.
[16-year-old focus group participant accepting HPV
vaccination]
I had already been with someone before I got the shot
and I knew that it didn’t protect 100%. But it was
still an advantage to get it. And I think that the
reason I got the shot was because my mother insisted
that I was going to get it and that she’dp a y .B u tI
think that if I had to pay for it myself or if she
hadn’t been so keen that I should have it, I don’t
think anything would have come of it. Because I’ma
bit sluggish some times. I often say to myself that I
should get a bicycle helmet, and I’ve said so for years
because I bike so much and it would be an obvious
advantage to me. But I just never have got one. So, I
think the same could have happened with this [24-
year-old focus group participant accepting HPV
vaccination]
Results across the quantitative and qualitative studies:
Barriers to HPV vaccination
In the survey, among women rejecting HPV vaccination,
cost was cited as the greatest barrier to accepting HPV
vaccination, particularly for the younger participants
(Table 4). The second most frequent reason given was
that it was too late, particularly for the older survey par-
ticipants. Only a few survey participants said they were
against vaccines in general, feared side-effects or found
it too inconvenient to have three injections within six
months. Very few women in the survey refused the vac-
cine because they thought they had a low risk of
infection.
Lack of information
Many of the focus group participants rejecting HPV vac-
cination explained that all the vaccines they knew were
recommended as part of the childhood-immunisation
programme or required for travel to certain destinations.
Therefore, many of them found it strange that the deci-
sion to be HPV vaccinated was theirs.
It h i n ki t ’s strange...I’ve never had a vaccine that
wasn’t required or that I had to have because I was
Table 3 Where did you hear about HPV vaccination
Women accepting HPV vaccination (%) Women rejecting HPV vaccination (%)
Age 16-20 years (N = 100) Age 21-26 years (N = 101) Age 16-20 years (N = 102) Age 21-26 years (N = 132)
Parents 50 31 13 8
TV 31 39 61 68
Friends 28 27 40 32
GP 21 28 19 18
Posters/brochures 14 15 14 22
Place of education 12 6 19 16
Other
a 13 16 5 7
Internet 4 6 7 10
Siblings 4 5 8 2
Radio 1 3 2 7
Place of work 1 2 2 3
Partner 1 2
aOther mostly including other family members and fellow students
Mortensen BMC Public Health 2010, 10:68
http://www.biomedcentral.com/1471-2458/10/68
Page 8 of 14going to be travelling. Then suddenly a vaccine
arrives that we can choose to have or not. And I
think that’s difficult because that’s not something you
just do. It’s probably best to find out what it does.
What is involved? Does it even protect me against
this disease, or what? I think that’s the odd part of
this vaccine. It’s a bit different from what we’re used
to. [17-year-old focus group participant refusing HPV
vaccination]
These focus group participants felt they should be bet-
ter informed before taking the decision because it was
optional. They needed information like:
￿ Which diseases does it prevent?
￿ Does it work when you’ve already been sexually
active?
￿ Is there any way of knowing whether you’ve been
exposed to HPV?
￿ Why aren’t boys vaccinated against HPV?
The focus group participants rejecting HPV vaccina-
tion generally wished that they had received the vaccine
via the childhood-immunisation programme when it
was free of charge and would certainly have been effec-
tive.
Most people don’t know that much. They can’tc o m e
to a decision. But I know a few people who got it as
soon as they heard of it. Not many people I know are
entirely against it. They hesitate because they don’t
know enough about it. [18-year-old focus group parti-
cipant refusing HPV vaccination]
Not being in the target group
The focus group participants aged 21-26 years who
refused HPV vaccination were under the impression
that they were not in the target group. Most had not
actively decided against being vaccinated or considered
that they might already be infected with HPV; they sim-
ply thought that the vaccine was not targeted to women
after sexual debut. Some said they thought that it was
too late if they had had more than five sexual partners.
My choice isn’tr e a l l ya na c t i v eo n e ,s oi t ’sn o tl i k eI
don’t want the vaccine as such. It’s mostly that I
thought that that ship had already sailed, that it
was simply too late, so that the money would be
wasted. [26-year-old focus group participant refusing
HPV vaccination]
In addition, the women who were in steady relation-
ships in the focus group of 21-26-year-olds thought that
this excluded them from the target group; they particu-
larly felt safe if they had also had a negative cervical-
smear result. The fact that almost one-third of the sur-
vey participants refusing HPV vaccination had not dis-
cussed the vaccine with anyone, could be due to this
consideration that the vaccine was not relevant to them.
Cost versus vaccine benefits for sexually active women
Many of the younger focus group participants said that
if the vaccine was cheaper or free of charge they would
have been vaccinated. The few women who were not yet
sexually active said they hoped to be able to afford the
vaccine before it was too late.
It’s because you have to pay for it yourself. The rea-
son that I’m in this group, clearly, it’s not that I
don’t want this vaccine. Of course I do. But I can’t
afford to pay 3500 Danish kroner [470 euros] for it.
Many people of our age, well, they’re young people,
still students, and perhaps they have a part-time job.
But only few girls around the age of 16 can afford it,
Table 4 Main reasons for rejecting HPV vaccination
Reason Women rejecting vaccination (%)
16-20 years old
(N = 102)
21-26 years old
(N = 132)
Vaccine too expensive 72 51
Too late/already sexually active 15 41
Other
a 20 26
Low risk of cervical cancer 9 6
Low risk of HPV infection 6 4
Fear of side-effects 3 7
Against having too many vaccines 5 3
Against all vaccinations 3 0
Don’t have time for it 2 0
Inconvenience (three injections within six months) 2 0
Too young/not yet relevant 1 0
aOther: being already sexually active or not being in the target group.
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focus group participant refusing HPV vaccination]
The focus group participants rejecting HPV vaccina-
tion said they needed clear recommendations from the
health authorities, their own GP or independent medical
societies such as the Danish Cancer Society to justify
spending so much money on the vaccine. None of their
G P sh a dr e c o m m e n d e dt h a tt h e ys h o u l db ev a c c i n a t e d .
Several of these focus group participants were sure that
their parents would help to pay for the vaccine if they
were convinced that it was beneficial. In other words,
their decision was also determined by the balance
between cost and the perception of benefit. The focus
group participants rejecting vaccination stated that the
absence of recommendations significantly decreased
their willingness to pay, but if the vaccine was free of
charge, they would feel less need for knowledge.
The cost stops many of my friends, but they also feel
uncertain of whether they’re in the target-group -
whether you can even get it if you’ve been sexually
active. To me, the price is decisive. If the vaccine was
free, I would have just rushed to the doctor and had
it done no matter if it worked or not - or how sexu-
ally active I’d been. I would have just got it over and
done with. But because of the price, no matter what,
I’m not going to spend 3500 Danish kroner [470
euros] on it, that’s for sure. [18-year-old focus group
participant rejecting HPV vaccination]
When asked, the other women in this focus group
agreed that they would have been vaccinated if the vac-
cine was free of charge.
Some of the younger focus group participants reject-
ing vaccination reflected that not knowing any women
of their age who had had cervical-cell changes or cervi-
cal cancer also made the threat of HPV infection more
distant. Among the older focus group participants, many
knew of women who had had cell changes but none had
knowingly been exposed to HPV themselves. This sug-
gests that a lack of personal experience with HPV infec-
tion can indeed act as a barrier to vaccination.
The focus group participants rejecting HPV vaccina-
tion did not themselves raise the subject of genital
warts. When asked, only one of the younger and three
of the older women had heard that the vaccine could
prevent genital warts. Their knowledge about genital
warts was generally lacking and their prevention was
n o tp a r to ft h ef o c u sg r o u pp a r t i c i p a n t s ’ considerations
regarding HPV vaccination.
The interpretation of health-policy decisions
The fact that, in Denmark, HPV vaccination is free of
charge only for girls aged 12-15 years was, according to
some focus group participants, a question of economic
priority: the vaccine was offered to those who were sure
to benefit because they had not yet become sexually
active. However, many focus group participants were
under the impression that the choice of target group
was based on a purely medical assessment: the vaccine
would have been free for older girls/women if there was
a chance that this age group might benefit from it. By
t h es a m er e a s o n i n g ,s o m ef o c u sg r o u pp a r t i c i p a n t s
assumed that the lack of information provided to
women older than age 15 years was an indicator that
the vaccine was not relevant in this case.
I think that only two of my friends have had the vac-
cine because...the fact that it’s paid for up until the
age of 15, I think, gives many of my friends aged 20-
21 the impression that if you didn’t get it then, it
doesn’th e l p .Y o u ’re too old for it. That’s kind of the
signal that’ss e n tb yo n l yg i v i n gi tt og i r l su pt oa g e
15 years. A lot of my friends don’t even consider it
because they’ve got that impression. [20-year-old
focus group participant rejecting HPV vaccination]
When it isn’t free of charge for us, you assume that
we’re not in the group that it would help otherwise,
it would surely have been free of charge for us as
well, if it had any effect. When it’s not, you think
that it’s like those people who get an influenza vac-
cine although they’r en o te v e na tr i s k ,t h a ti t ’sp r o b -
ably overkill to get this vaccine, because it’s too late
anyway. [24-year-old focus group participant reject-
ing HPV vaccination]
Yes, that’s sort of the implicit message: that we don’t
get it for free because it doesn’th e l p .T h a ti fi tm i g h t
help us, at least, we’d receive some sort of subsidy or
we’d be recommended to go and get it. [another 24-
year-old focus group participant rejecting HPV
vaccination]
The effect of vaccination on other methods of preventing
HPV-related diseases
The focus groups pointed to the potential effects of
HPV vaccination on other means of preventing HPV-
related diseases. The women rejecting HPV vaccination
believed that use of condoms was important to prevent
all STIs, but not all were aware that condom use can
only reduce and not entirely eliminate the risk of HPV
infection. Moreover, many mentioned the fact that the
use of condoms is often discarded after a few months in
a steady relationship.
Many of the older focus group participants rejecting
vaccination pointed to the cervical cancer-screening pro-
gramme as a means to detect cell changes at an early
stage and prevent cervical cancer. Some worried that
HPV vaccination might produce a false sense of security
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condom use or participation in the screening
programme.
When asked, most focus group participants accepting
HPV vaccination said that women should still have reg-
ular cervical-smear tests. However, their impression that
the vaccine did not confer total protection was, again,
related to the effectiveness of vaccination after the onset
of sexual activity rather than to an understanding that
the vaccine protects against only the two most common
HPV types that cause cervical cancer and not against
those causing the remaining 30% of cases. One focus
group participant thought that the importance of
screening would decrease because HPV vaccination
would now prevent most cases of cervical cancer.
Others thought that they might themselves become less
concerned about attending check-ups, because of an
increased sense of security after vaccination.
Perhaps, I’ll become a bit more easy-going about it,
like, now that I’ve got the vaccine, I’ll feel a bit safer.
[16-year-old focus group participant accepting HPV
vaccination]
At the very least, I’m going to get my first check when
I turn 23. I’m definitely going to do that just to make
sure. I could have had the virus before I got the vac-
cine. But after that, I imagine that I’ll be a bit
more...well, I’ll feel that I won’t need it every three
years, at least. I’ll probably become a bit more care-
less [20-year-old focus group participant accepting
HPV vaccination]
These statements went uncontested in the focus group
and seemed to make sense to more of the younger par-
ticipants. Although most focus group participants
accepting HPV vaccination said that they would still use
condoms to prevent other sexually transmitted diseases
and pregnancy, those in steady relationships said they
felt safer after vaccination, and this contributed to the
sense of making a fresh start.
Discussion
In this study of drivers and barriers to young women’s
choices about HPV vaccination, a literature review, a tel-
ephone interview-based survey and interviews with focus
groups were combined methodologically. This triangula-
tion of methods was used to ensure the validity and
reliability of the study in the sense that it built upon
existing knowledge, it sought to answer the research
questions quantitatively by means of the survey and
qualitatively to obtain an in-depth understanding of
women’s considerations.
The telephone survey provided quantitative data about
the women accepting and rejecting HPV vaccination,
including how many of those who wished to be vacci-
nated actually started the vaccination series and infor-
mation about the most important factors influencing
women’s acceptance or rejection. The strength of focus
groups lies in the insights they provide into the social
forces acting on individual understandings of the area of
interest. Interviews with focus groups in this study have
produced a multi-faceted view of the ways in which
Danish women’s considerations about HPV vaccination
relate to broader socio-cultural perceptions of cancer,
sexuality and norms of equal access to health care.
However, the social control that characterise group
interviews mean that focus groups are less suitable for
producing data about individual lives or narratives; for
example, atypical individual understandings may be
under-reported in focus groups [48].
This is one of the first studies to be conducted after
the quadrivalent HPV vaccine became readily available
in Denmark. It sheds light on the relationship between
intention and action and the balance of factors that can
encourage or hinder the translation of the intention to
be vaccinated into the action of initiating vaccination in
this specific socio-cultural context. While we believe
that the many of these results are likely to be relevant
and applicable to other societies, this thorough analysis
of what is at stake in Denmark implies that they may
not all be directly transferable to other countries. Per-
ceptions of illnesses and preventive measures are always
related to the specific socio-cultural context and health
care system - and in this case also the particular infor-
mation campaign. Whether the results of this study can
be transferred to other societies thus remains to be
shown.
This survey showed that most young Danish women
have heard of vaccination against cervical cancer, but
nearly one in five has not yet decided whether they
want to be vaccinated. More than half of the women
interviewed by telephone said they wanted to be vacci-
nated, but only half of these had actually started or
completed the vaccination series. Since earlier studies
found in the literature review have pointed to a very
high acceptance rate, internationally and in Denmark,
this suggests that the difference between intention and
action can be considerable. Approximately one third of
the women interviewed by telephone rejected HPV vac-
cination, but the focus groups suggested that this pic-
ture could change, provided that the barriers to
vaccination were addressed.
This study did not show any opposition to the HPV
vaccine as such, and participants in the qualitative study
all had positive views on vaccination against cervical
cancer. This also mirrors the high level of vaccine
acceptance reported in earlier studies. Our participants
mostly considered HPV vaccination as a means to
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been the focus of the Danish information strategy. The
focus groups revealed that the actual risk of acquiring
cervical cancer was not considered. However, as sug-
gested by other studies [21,24,40], our results show that
women who have previously and knowingly been
exposed to HPV-related diseases, or who know of peo-
ple who have had HPV-related diseases or cancer, tend
to be more accepting of vaccination.
Knowledge about genital warts was very limited
among the focus group participants. This finding is sup-
ported by a recent study in which only 0.7% of Danish
women assigned HPV as the cause of genital warts [57].
Thus this factor was not part of the women’s considera-
tion about HPV vaccination, although the fact that the
vaccine could prevent 90% of cases of genital warts was
seen as an additional benefit. Other studies have sug-
gested that the information that the quadrivalent vaccine
can prevent genital warts considerably increases men’s
acceptance of HPV vaccination [39], and our qualitative
study indicates that the same effect might be observed
for women.
Attitudes to the fact that HPV is transmitted sexually are
highly dependent on the prevalent sexual morals in a
society and need further investigation. In contrast to the
results of some USA-based studies [11,13,16,19-21], for
example, Danish men and women do not consider the
mode of transmission of HPV as a barrier to HPV vaccina-
tion. On the contrary, they found that the mode of trans-
mission increased the relevance of HPV vaccination of
both sexes [10]. The present study also suggests that Dan-
ish women do not regard sexual abstinence before mar-
riage as a realistic means of prevention of HPV infection.
The qualitative study confirmed earlier reports that
Danish women’s knowledge about HPV, cervical dyspla-
sia and the properties of the HPV vaccine is generally
poor. For example, in one study only 1.2% of Danish
women were able to name HPV as the cause of cervical
cancer [57]. Our study reveals that most focus group
participants were under the impression that HPV vacci-
nation provides full protection against cervical cancer, if
given before the start of sexual activity. It is important
that this misconception be investigated further since,
although it may promote the uptake of vaccination, it
may also encourage a false sense of security, e.g. some
focus group participants indicated that they would be
less concerned by the risk of HPV infection after HPV
vaccination, especially if they had concurrently received
a negative smear-test result. This highlights the danger
that HPV vaccination might reduce uptake of other pre-
ventive measures, such as use of condoms and participa-
tion in the cervical cancer-screening programmes, which
should ensure the maximal public health benefit for
HPV vaccination.
Most of the focus group participants who had rejected
HPV vaccination said they would actually like to be vac-
cinated if they could be convinced of the benefits. The
most important factors influencing rejection were uncer-
tainty or ignorance of the benefits of vaccination after
the onset of sexual activity and the cost, which many
regarded as very high. This was a confirmation of the
results of the Danish HTA showing that young women
were not likely not be vaccinated if they were to pay for
it themselves. Our qualitative study shows that the lack
of knowledge was less important when the vaccine was
paid for by someone else, but became a decisive factor
when the young woman had to pay herself.
We report that parental advice and financial support is
very important to young women’sa c c e p t a n c eo fH P V
vaccination. Proactive mothers, in particular, had great
power to persuade their daughters to take active steps
towards vaccination. The survey showed that acceptance
of vaccination was associated with a higher level of edu-
cation of the parents, although it is impossible to say
whether the choice was influenced by the parents’ edu-
c a t i o n a ll e v e lo rb yt h ep o t e n t i a lh i g h e ri n c o m e .G P s
tended not to initiate talks with the young women about
HPV vaccination, but when they did, or were consulted
for this reason, they could also significantly influence
the woman’s choice. In contrast, women in the survey
whose primary source of information was the media
tended to think that HPV vaccination was not relevant
to them, that they were insufficiently informed and con-
sequently more frequently rejected vaccination.
The high coverage of the free HPV-vaccination pro-
gramme for girls aged 12-15 years in Denmark supports
the finding that the cost is very important to women’s
acceptance of vaccination. The focus group participants
in our study had great confidence in the Danish health
authorities and inclusion of HPV vaccination in this
programme was regarded as approval of the safety and
effectiveness of the vaccine. Conversely, they considered
the decision not to include or inform women above the
age of 15 years as an indication that this vaccine was
not medically recommended for older girls or women.
Our study shows that the fact that HPV vaccination is
optional for women over 15 years old raises questions in
it self and provokes uncertainty that can result in rejec-
t i o n ,e v e nw h e nt h e s ew o m e no rt h e i rp a r e n t sa r ea b l e
to afford vaccination. As other studies have shown, Dan-
ish women have a strong expectation that their GP will
inform them of any necessary preventive health care
measures, such as HPV vaccination [57]. In light of the
relatively high cost of the vaccine, medical authorities
and health-care professionals must disseminate clear
recommendations and information about HPV vaccina-
tion targeted to young women who are already sexually
active if such women, or their parents, are to be
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to pay.
Conclusions
Our survey among Danish women aged 16-26 years who
have heard of HPV vaccination shows that nearly a fifth
had not yet decided whether they want to be vaccinated
and only a quarter had actually started or completed
vaccination. As results from earlier studies reported that
the intended acceptance was 70-90%, our results suggest
that the difference between intention and action is con-
siderable. Noteworthy drivers to acceptance of vaccina-
tion are parental financial support and recommendation
by parents, medical authorities or a general practitioner.
If the most important barriers to HPV vaccination -
namely, the cost and the lack of information about the
benefits of vaccination for sexually active women - were
to be addressed, it is likely that uptake of HPV vaccina-
tion would increase significantly in Denmark. This
would accelerate the reductions in incidence of cervical
dysplasia, cervical cancer and genital warts already
expected to be achieved by including the HPV vaccine
in the childhood-immunisation programme.
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